-
Sector Analysis
Tackling Drug Prices in the US (White Paper)
GlobalData is pleased to announce the release of a special white paper covering the latest disruptions in US drug pricing. Use this report to: Learn more about the US healthcare system in general, medicines' pricing and reimbursement, and the latest events disrupting the pharmaceutical market. Understand and evaluate the impact the latest US reforms will have on medicines' prices, reimbursement and market access worldwide
-
Thematic Analysis
State of the Biopharmaceutical Industry 2026 (Mid-Year Update) Edition
Report Value Proposition – Why This Matters for You The biopharmaceutical industry enters 2026 facing a rapidly evolving landscape shaped by artificial intelligence adoption, regulatory changes, pricing pressures, geopolitical uncertainty, and increasing competition for innovation leadership. This report helps stakeholders understand the trends that will define biopharma performance over the next 12 months, covering R&D productivity, commercialization strategies, market access challenges, investment sentiment, and emerging growth opportunities. Drawing on industry surveys, proprietary market intelligence, and expert analyst insight, the report...
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, May 2026
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
-
Sector Analysis
Nasal Polyps (Nasal Polyposis) and CRSwNP (Chronic Rhinosinusitis with Nasal Polyps): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Nasal Polyps (Nasal Polyposis) and CRSwNP (Chronic Rhinosinusitis with Nasal Polyps) Therapeutics. In 2025, there were more than 5.15 million diagnosed incident cases of nasal polyps and CRSwNP in the 16 countries covered in GlobalData’s epidemiology forecast. The current treatment landscape for nasal polyps primarily involves intranasal corticosteroids, oral corticosteroids for severe cases, and functional endoscopic sinus surgery for patients unresponsive to medical therapy, with biologics...
-
Sector Analysis
Chronic Kidney Disease: Epidemiology Report and Forecast to 2035
Chronic kidney disease (CKD), or chronic renal disease (International Classification of Diseases 10th Revision [ICD-10] code = N18), is a condition characterized by a gradual loss of kidney function over time. This leads to the accumulation of excess fluid and waste in the body. In the early stages, CKD is a largely asymptomatic condition. As the disease progresses, symptoms worsen and eventually lead to kidney failure (Centers for Disease Control and Prevention, 2024). Advanced CKD can lead to dangerous levels...
-
Sector Analysis
Male Infertility Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
Report Value Proposition – Why Does the Male Infertility Therapeutics Market Matter? Male infertility remains an important yet underserved therapeutic area, with growing attention on improving diagnosis, understanding disease mechanisms, and developing targeted treatment options. Although diagnosed prevalence is expected to remain relatively stable across the seven major pharmaceutical markets (7MM), significant unmet clinical needs and limited approved therapies continue to create opportunities for innovation and investment. GlobalData's Male Infertility Therapeutics Market Analysis provides a comprehensive assessment of the market...
-
Product Insights
Clinical Trials: A Dive into Clinical Trial Sites
The clinical trials data used for these analyses was extracted from GlobalData’s Clinical Trials Database. The data included clinical trial sites used in clinical trials with a start date between January 1, 2020, and December 31, 2025, which were captured in the database as of April 21, 2026. The trial sites were analyzed and segmented by phase, status, sponsor type (industry versus non-industry), top sponsors, top CROs, geography, therapy area, and indication.
-
Sector Analysis
Slovakia's WTP Thresholds for Drug Reimbursement Evaluations - An Uncertain Future for Innovation
GlobalData takes a detailed look at the changing willingness-to-pay (WTP) thresholds for drug reimbursement evaluations in Slovakia, in the midst of regulatory uncertainty following the withdrawal of a proposed draft decree in May 2025, which would have drastically worsened the prospects for new innovative therapies in the country.
-
Sector Analysis
Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Therapeutics. In 2025, there were more than 1.12 million diagnosed prevalent cases of PBC in the 16 countries covered in GlobalData’s epidemiology forecast. Currently, the PBC market is saturated with generic drugs and has a limited number of approved drugs available to treat PBC. The DR pipeline holds 32 molecules, with no assets in the pre-registration stage, four assets in...
-
Sector Analysis
The Keytruda Patent Cliff: Pricing Dynamics Following Biosimilar Competition
As a blockbuster therapy in immuno-oncology, Keytruda has undoubtedly established itself as one of the most clinical and commercially successful medicines across the global biopharmaceutical landscape. Its upcoming loss of exclusivity therefore represents one of the most consequential and prominent events in the global oncology market, with far-reaching pricing implications.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.